Eosinophilic Granulomatosis With Polyangiitis Following COVID-19 Vaccination: A Case Report

Hwang, Yu-Kyoung; Kwak, Hui-Hwan; Yun, Jeong-Eun; Kim, Sae-Hoon; Chang, Yoon-Seok

doi:10.3346/jkms.2023.38.e382

Cited by 2 publications

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Unexpected Hypereosinophilia after Sinopharm Vaccination: A Case Report

Dalfardi,

Rad,

Alizade

et al. 2024

Preprint

View full text Add to dashboard Cite

COVID-19 vaccines have been associated with various adverse events, though their safety profile is generally favorable. We present a case of a 66-year-old male who developed hypereosinophilia (Absolute eosinophil count: 4063 cells/µL) and lymphadenopathy following the third dose of the Sinopharm COVID-19 vaccine. Despite extensive investigations, an underlying cause for these findings was not identified. While a causal relationship cannot be definitively established, the temporal association between the vaccine and symptom onset is intriguing. This case highlights the importance of continued surveillance for rare adverse events following vaccination and emphasizes the need for further research to understand the potential mechanisms linking COVID-19 vaccines to eosinophilic disorders.

show abstract

Unexpected Hypereosinophilia after Sinopharm Vaccination: A Case Report

Dalfardi,

Rad,

Alizade

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

ANCA-Positive Small-Vessel Vasculitis Following SARS-CoV-2 Vaccination—A Systematic Review

Łysak,

Walulik,

Błaszkiewicz

et al. 2024

Vaccines

View full text Add to dashboard Cite

As vaccinations against the SARS-CoV-2 virus have become a crucial tool in controlling the spread of the disease, reports of rare health complications have emerged, including new-onset antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV). We systematically reviewed new-onset AAV following COVID-19 vaccination case reports and case series published in three databases before January 2024 following PRISMA guidelines to understand the characteristics of possible causal relationships or coincidences. In total, 404 articles were screened respectively by title, abstracts, and full-texts. Thirty-four papers fulfilled the inclusion criteria and have been analyzed, covering 44 patients with new-onset AAV after COVID-19 vaccination with no prior history of COVID-19 infection. Data regarding patients’ metrics, comorbidities, vaccination characteristics, symptoms, diagnostics, treatment, and outcomes were investigated and summarized. The cohort consisted predominantly of females. AAV diagnosis was confirmed via biopsy, with renal dysfunction as a prevailing manifestation. In most cases, the first symptoms of AAV developed after the second dose; moreover, Pfizer-BioNTech was the most frequently administered vaccine among the analyzed cohort. Primary treatment involved glucocorticoid therapy, with a mostly favourable response. This systematic review aims to raise awareness among clinicians in the field regarding this rare but possible complication, to promote the prompt recognition and diagnosis of de novo ANCA-positive small-vessel vasculitis in timely association with SARS-CoV-2 vaccination.

show abstract

Eosinophilic Granulomatosis With Polyangiitis Following COVID-19 Vaccination: A Case Report

Cited by 2 publications

References 24 publications

Unexpected Hypereosinophilia after Sinopharm Vaccination: A Case Report

Unexpected Hypereosinophilia after Sinopharm Vaccination: A Case Report

ANCA-Positive Small-Vessel Vasculitis Following SARS-CoV-2 Vaccination—A Systematic Review

Contact Info

Product

Resources

About